<DOC>
	<DOCNO>NCT01216085</DOCNO>
	<brief_summary>This study locally amend study CSTI571K2301 evaluate efficacy safety high-dose Glivec Korean patient group chronic phase CML . Molecular response 60 month Glivec administration describe .</brief_summary>
	<brief_title>An Exploratory Study High-dose Glivec Patients With CML-CP Using Molecular Endpoints</brief_title>
	<detailed_description />
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . TOPS ( CSTI571K2301 ) participant patient take Glivec 400 mg daily 30 July , 2010 , close date TOPS 2 . Patients provide write informed consent prior participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>